FRM
AZN icon

Fox Run Management’s AstraZeneca AZN Stock Holding History

Fox Run Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,663
Closed -$322K – 931
2026
Q1 		$322K Buy
+1,663
New +$321K 0.06% 600
2025
Q3 		– Sell
-7,112
Closed -$994K – 914
2025
Q2 		$994K Sell
7,112
-5,333
-43% -$747K 0.17% 192
2025
Q1 		$1.83M Buy
12,445
+1,138
+10% +$165K 0.28% 41
2024
Q4 		$1.48M Buy
+11,307
New +$1.58M 0.27% 59
2024
Q3 		– Sell
-6,223
Closed -$971K – 802
2024
Q2 		$971K Sell
6,223
-573
-8% -$86.2K 0.18% 197
2024
Q1 		$921K Buy
+6,796
New +$900K 0.2% 153
2023
Q3 		– Sell
-5,065
Closed -$725K – 704
2023
Q2 		$725K Buy
+5,065
New +$745K 0.2% 170
2023
Q1 		– Sell
-3,677
Closed -$499K – 654
2022
Q4 		$499K Buy
+3,677
New +$461K 0.2% 180
2022
Q1 		– Sell
-2,438
Closed -$284K – 499
2021
Q4 		$284K Buy
+2,438
New +$287K 0.17% 245
2019
Q4 		– Sell
-2,841
Closed -$253K – 384
2019
Q3 		$253K Buy
+2,841
New +$246K 0.23% 218
2019
Q2 		– Sell
-9,323
Closed -$754K – 433
2019
Q1 		$754K Sell
9,323
-128
-1% -$10.1K 0.43% 25
2018
Q4 		$718K Buy
+9,451
New +$738K 0.38% 33
2018
Q3 		– Sell
-4,350
Closed -$305K – 576
2018
Q2 		$305K Sell
4,350
-7,781
-64% -$560K 0.1% 426
2018
Q1 		$848K Buy
+12,131
New +$840K 0.21% 124
2017
Q4 		– Sell
-14,050
Closed -$952K – 669
2017
Q3 		$952K Buy
14,050
+2,200
+19% +$139K 0.27% 80
2017
Q2 		$808K Buy
+11,850
New +$774K 0.28% 85
2016
Q4 		– Sell
-6,350
Closed -$417K – 500
2016
Q3 		$417K Buy
+6,350
New +$415K 0.25% 151

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fox Run Management's AZN Position: Q2 2026 in Review

Fox Run Management sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 1,663 shares — an estimated $322K sold.

Fox Run Management first reported a position in AZN in Q3 2016 and held it in 17 quarters. The position peaked at $1.83M in Q1 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Fox Run Management reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 1,663 AstraZeneca shares in Q2 2026, an estimated $322K.
  • Fox Run Management first reported a position in AstraZeneca in Q3 2016 and held it in 17 quarters.
  • Fox Run Management's AstraZeneca position peaked at $1.83M in Q1 2025.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.